BSX

Boston Scientific (BSX) Price Target Increased by 10.12% to 72.24

The average one-year price target for Boston Scientific (NYSE:BSX) has been revised to 72.24 / share. This is an increase of 10.12% from the prior estimate of 65.60 dated January 16, 2024.

The price target is an average of many targets provided by analysts. The latest targets range from a low of 61.61 to a high of 85.05 / share. The average price target represents an increase of 7.82% from the latest reported closing price of 67.00 / share.

What is the Fund Sentiment?

There are 2182 funds or institutions reporting positions in Boston Scientific. This is an increase of 87 owner(s) or 4.15% in the last quarter. Average portfolio weight of all funds dedicated to BSX is 0.49%, a decrease of 2.32%. Total shares owned by institutions increased in the last three months by 0.89% to 1,512,490K shares. BSX / Boston Scientific Corporation Put/Call Ratios The put/call ratio of BSX is 1.12, indicating a bearish outlook.

What are Other Shareholders Doing?

BSX / Boston Scientific Corporation Shares Held by Institutions

Massachusetts Financial Services holds 57,176K shares representing 3.90% ownership of the company. In it's prior filing, the firm reported owning 62,533K shares, representing a decrease of 9.37%. The firm decreased its portfolio allocation in BSX by 7.67% over the last quarter.

VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 45,600K shares representing 3.11% ownership of the company. In it's prior filing, the firm reported owning 45,631K shares, representing a decrease of 0.07%. The firm increased its portfolio allocation in BSX by 1.25% over the last quarter.

Primecap Management holds 37,906K shares representing 2.59% ownership of the company. In it's prior filing, the firm reported owning 37,355K shares, representing an increase of 1.45%. The firm increased its portfolio allocation in BSX by 4.20% over the last quarter.

Wellington Management Group Llp holds 36,441K shares representing 2.49% ownership of the company. In it's prior filing, the firm reported owning 42,077K shares, representing a decrease of 15.46%. The firm decreased its portfolio allocation in BSX by 89.57% over the last quarter.

VFINX - Vanguard 500 Index Fund Investor Shares holds 35,185K shares representing 2.40% ownership of the company. In it's prior filing, the firm reported owning 34,231K shares, representing an increase of 2.71%. The firm increased its portfolio allocation in BSX by 2.73% over the last quarter.

Boston Scientific Background Information
(This description is provided by the company.)

Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 40 years, The company advances science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare.

Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.

Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.

Click to Learn More

This story originally appeared on Fintel.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tags

More Related Articles

Info icon

This data feed is not available at this time.

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.